PepTrackevidence-graded reference
Melanotan II
fig.1 — stylized molecular motif
Cosmetic / skin

Melanotan II

MT-II · MT2

High consumer recognition (tanning + libido); 460M+ TikTok views for 'nasal tanning'. Distinct from FDA-approved afamelanotide (Scenesse).

Evidence
Bhuman trials
Status
Banned / prohibitedas of 2026-06
Approval
Not approved
Category
Cosmetic / skin
Route
Subcutaneous · Intranasal
Demand rank
honorable mention
01Dosing & Protocol
Typical · reference only
Loading ~100-250 mcg/day, then ~500-1000 mcg 1-2x/week maintenance SC
Titration
Start low to gauge nausea/BP
Reconstitution — illustrative, not a recommendation
10 mg vial + 2 mL BAC = 5 mg/mL; 500 mcg = 10 U on U-100. Intranasal absorption is unpredictable - mcg figures don't translate.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. Banned as a medicine in the UK; Schedule 9 (prohibited) in Australia (Feb 2026).
Status
Banned / prohibited
503A bulks
Not on the bulks list
Category 2
Removed from Category 2 ~22 Apr 2026; on the ~Feb 2027 PCAC
PCAC review
~2027-02
WADA
Not listed
03Evidence — the honest read
What the evidence actually shows

Early-phase human + small tanning studies; NO approval. Evidence is largely evidence of HARM (case reports).

04Safety
Contraindications
  • Melanoma / dysplastic nevi / skin-cancer historyhard stop
  • Uncontrolled hypertension / known CVDhard stop
  • History of priapism / sickle cell
  • Pregnancyhard stop
Key interactions
  • PDE5 inhibitors (HARD_STOP/avoid; severe hypotension/syncope + priapism)
Serious signals
  • Priapism (urologic emergency)
  • PRES; rhabdomyolysis; renal infarction (case reports)
  • Mole darkening / new nevi / melanoma - complicates surveillance
Monitoring
Regular dermatologic mole surveillance; baseline BP.
05Related in Cosmetic / skin
GHK-Cu
human trials
grade B →
06Sources
1TGA Schedule 9 2026; case reports
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: medium
← All peptides
Cosmetic / skin

Melanotan II

MT-II · MT2

High consumer recognition (tanning + libido); 460M+ TikTok views for 'nasal tanning'. Distinct from FDA-approved afamelanotide (Scenesse).

Evidence
B
human trials
Status
Banned / prohibited
as of 2026-06
FDA approval
Not approved
off-label / gray
Route
Subcutaneous · Intranasal
Community / anecdotal
Demand
—
honorable mention
WADA
Not listed
sport-legal
01

Dosing & protocol

Community / anecdotal. Community / anecdotal — no regulatory basis. Not medical advice.
Typical — reference only

Loading ~100-250 mcg/day, then ~500-1000 mcg 1-2x/week maintenance SC

Worked reconstitution example

10 mg vial + 2 mL BAC = 5 mg/mL; 500 mcg = 10 U on U-100. Intranasal absorption is unpredictable - mcg figures don't translate.

Titration

Start low to gauge nausea/BP

Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. Banned as a medicine in the UK; Schedule 9 (prohibited) in Australia (Feb 2026).
StatusBanned / prohibited
503A bulksNot on the bulks list
Category 2 (2026)Removed from Category 2 ~22 Apr 2026; on the ~Feb 2027 PCAC
PCAC review~2027-02
WADANot listed
03

Evidence — the honest read

Bhuman trials

Early-phase human + small tanning studies; NO approval. Evidence is largely evidence of HARM (case reports).

04

Safety

Contraindications
  • Melanoma / dysplastic nevi / skin-cancer historyhard stop
  • Uncontrolled hypertension / known CVDhard stop
  • History of priapism / sickle cell
  • Pregnancyhard stop
Key interactions
  • PDE5 inhibitors (HARD_STOP/avoid; severe hypotension/syncope + priapism)
Serious signals
  • Priapism (urologic emergency)
  • PRES; rhabdomyolysis; renal infarction (case reports)
  • Mole darkening / new nevi / melanoma - complicates surveillance
Monitoring

Regular dermatologic mole surveillance; baseline BP.

06

Sources

01TGA Schedule 9 2026; case reports
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: medium